Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes

Title: Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes

Volume: 8 Issue: 7

Author(s): Clarence Hale and Minghan Wang

Affiliation:

Keywords: 11β-hydroxysteroid dehydrogenase, glucocorticoid receptor, cortisol, ex vivo activity, insulin resistance, Cushing's syndrome

Abstract: Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11β-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.

Cite this article as:

Hale Clarence and Wang Minghan, Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes, Mini-Reviews in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/138955708784567421